Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera

• Published in: Science translational medicine Vol. 7; no. 309; p. 309ra162
• Main Authors: Ngwuta, Joan O, Chen, Man, Modjarrad, Kayvon, Joyce, M Gordon, Kanekiyo, Masaru, Kumar, Azad, Yassine, Hadi M, Moin, Syed M, Killikelly, April M, Chuang, Gwo-Yu, Druz, Aliaksandr, Georgiev, Ivelin S, Rundlet, Emily J, Sastry, Mallika, Stewart-Jones, Guillaume B E, Yang, Yongping, Zhang, Baoshan, Nason, Martha C, Capella, Cristina, Peeples, Mark E, Ledgerwood, Julie E, McLellan, Jason S, Kwong, Peter D, Graham, Barney S
• Format: Journal Article
• Language: English
• Published: United States 14.10.2015
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Neutralizing - blood; Antibodies, Neutralizing - chemistry; Antibodies, Neutralizing - immunology; Antibodies, Neutralizing - isolation & purification; Antibodies, Viral - blood; Antibodies, Viral - chemistry; Antibodies, Viral - immunology; Antibodies, Viral - isolation & purification; Child; Humans; Middle Aged; Respiratory Syncytial Virus Vaccines - immunology; Respiratory Syncytial Viruses - chemistry; Respiratory Syncytial Viruses - immunology; Viral Fusion Proteins - chemistry; Viral Fusion Proteins - immunology; Young Adult

Respiratory syncytial virus (RSV) is estimated to claim more lives among infants <1 year old than any other single pathogen, except malaria, and poses a substantial global health burden. Viral entry is mediated by a type I fusion glycoprotein (F) that transitions from a metastable prefusion (pre-...